Axi-Cel and Liso-Cel Effective for LBCL Treatments – Real-World Studies

Here’s a ‍breakdown of ‍the real-world data shown with liso-cel in relapsed/refractory‍ LBCL, based on ‌the⁤ provided text:

Key Outcomes (from a study of patients, including those with ⁣comorbidities):

* ​ Median duration of ‌response: Approximately ⁢66%
* ‍ Progression-Free & ‍event-Free Survival (at 1 year): near 53%
* Overall Survival (OS) (at⁣ 1 year): About 71%
* ‍ Cytokine ‌Release Syndrome (CRS): ​ About 87% of patients experienced any-grade CRS. median⁢ duration⁣ was approximately ‌5 days.
* Neurotoxicity: about 50% of patients ⁣experienced neurotoxicity.Median duration was approximately ‌6 days.
* Prolonged Cytopenia (30+ days): ⁣ Approximately 16% of​ patients.
* non-Relapse Mortality (NRM) (at 6‌ months): Around 4% (low, even in a high-risk population).

Additional ‌Real-World Analysis:

* A real-world analysis ‌of liso-cel use in the second-line setting in high-risk ‍patients ⁣was conducted by investigators at the University of Utah (CIBMTR-based effort).
* ‍ This study included patients treated between June 2022 and August 2024.
* ⁤ ‌ The median​ age of patients in this study was a little older.